ClinicalTrials.gg
CompletedNCT00267488Updated Jul 11, 2012Results posted

Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer

A Phase 2 interventional study of topotecan in Neoplasms, Endometrial and Endometrial Cancer, sponsored by GlaxoSmithKline. Completed at 24 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-11.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Endometrial Neoplasms by GlaxoSmithKline — 7 open to participants now, 10 under way, 3 of them phase 3. Endometrial Neoplasms · GlaxoSmithKline.

Enrollment
9th of 13
70 · median 100
Started
2005
the only one that year
Phase 2
3 of 13
1 open now
Registered
1st of 13
by date

Among the 13 studies in Endometrial Neoplasms by GlaxoSmithKline, this one is the 9th largest by enrollment, is the only one that started in 2005, is one of 3 in phase 2, and was the 1st registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

7 of the 13 studies in Endometrial Neoplasms by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Endometrial Neoplasms by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to find out if Hycamtin given weekly is safe and effective for treating your endometrial cancer.

03

Conditions studied

  • Neoplasms, Endometrial
  • Endometrial Cancer

Keywords

  • Hycamtin
  • endometrial cancer
  • topotecan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A subject will be eligible for inclusion in this study only if all of the following criteria are met:
  • Subject has provided a written .
  • Subject must be female and ≥18 years of age.
  • Subjects' original endometrial carcinoma (any histologic type) must have had pathologic confirmation.
  • Subject must have recurrent or persistent endometrial cancer.
  • Subject must have at least one according to GOG-modified criteria.

    • Measurable disease must be accurately measured in at least one dimension (longest dimension to be recorded). Each lesion must be ≥ 20 mm when measured by conventional techniques, including palpation, plain X-ray, CT and MRI, or ≥10 mm when measured by spiral CT.
    • Measurable disease found on chest X-ray must be confirmed with CT or MRI. Either CT or MRI must be used throughout the study to further evaluate these lesions.
    • The same diagnostic method (CT, MRI, X-ray or physical exam) used to evaluate disease, must be used throughout the study to consistently evaluate lesions.
    • Palpable tumor masses that cannot be evaluated by CT or MRI scan should be evaluated by ultrasound or confirmed by .
    • Evaluable disease (measurable or non-measurable) may be in a field of prior radiation provided that at least six weeks have elapsed since receiving radiation and disease progression is clearly documented by radiographic study. It is preferential for the target lesion to be located outside an irradiated field.
    • Non-measurable disease is defined as all other lesions, including small lesions (longest diameter \<20 mm with conventional techniques or \<10 mm with spiral CT scan).
  • Subject has received one prior chemotherapy regimen (excluding all topoisomerase I inhibitors e.g., HYCAMTIN and irinotecan).
  • Subject is allowed to have received, but is not required to have received, one additional prior non-cytotoxic regimen for management of recurrent or persistent disease according to the following definition: Non-cytotoxic (biologic or cytostatic) agents include, but are not limited to, monoclonal antibodies, cytokines, and small molecule inhibitors of signal transduction. UM2004/00031/00 CONFIDENTIAL HCT100414 20
  • Subject is at least 21 days from prior chemotherapy and at least 30 days from prior non-cytotoxic therapy and is recovered from associated toxicities.
  • Subject must not have received radiotherapy for at least seven days.
  • Subject must be at least three weeks since last major surgery (a lesser period is acceptable if deemed in the best interest of the subject). Subject must have an Performance Status of 0 or 1 (refer to
  • Appendix 4, ECOG Performance Status).
  • Subject must have, at screening, a probable of at least three months.
  • Subject of must be practicing adequate [e.g., oral contraceptives, diaphragm plus spermicide, or intrauterine device (IUD)] or show documented complete abstinence from intercourse for at least three months prior to study start. The same contraceptive method should be used throughout the study and continue for at least four weeks after the end of the study. A subject will be considered of childbearing potential if not surgically sterile or (i.e., documented absence of menses for one year prior to entry into the study).

    1. Subject must have screening laboratory criteria as follows:
    • ≥ 9.0 g/dL.
    • Neutrophils ≥ 1,500/mm³ [≥1.5 x 10\^9/L].
    • ≥ 100,000/mm³ [≥100.0 x 10\^9/L].
    • Creatinine ≤ (ULN) or (Clcreat) ≥ 60mL/min.
    • Creatinine clearance should be calculated using the Cockcroft-Gault formula:

Clcreat (mL/min) = (140-age [yr] x body wt [kg] x 0.85 72 x serum creatinine [mg/dL] OR Clcreat (mL/min) = 1.05 x (140-age [yr] x body wt [kg] serum creatinine [μmol/L]

  • Serum within normal limits.
  • (AST), alanine aminotransferase (ALT) and alkaline phosphatase \< 2xULN if liver are absent by abdominal CT or MRI or \< 5xULN if liver metastases are present.

Exclusion criteria

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria are met:

  • Subject is pregnant or lactating.
  • Subject has received more than one prior chemotherapy regimen. UM2004/00031/00 CONFIDENTIAL HCT100414 21
  • Subject has concomitant or history of previous , with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease-free for five years.
  • Subject has active uncontrolled infection.
  • Subject has as documented by CT or MRI. Note: Asymptomatic subjects do not require CT or MRI to rule out brain metastases.
  • Subject has received prior treatment with HYCAMTIN.
  • Subject has a history of an allergic reaction to compounds chemically-related to HYCAMTIN or its constituents.
  • Subject has received any agent within 30 days or five half-lives (whichever is longer) prior to study entry.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Best Overall Response

    Tumor response based on GOG (Gynecological Oncology Group) modified RECIST (Response Evaluation Criteria In Solid Tumors) criteria. A 4-point scale used specifying tumor response. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions; (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; (PD): At least a 20% increase in the sum of the LD of target lesions

    Time frame: Week 0 to Week 98 when endpoints were met

Secondary outcomes

  1. Time to Progression

    Kaplan-Meier Estimate. Time to progression is defined as time from start of treatment until the first documented sign of disease progression or death due to progressive disease. Subjects who have not progressed or died at the time of analysis will be censored at the time of initiation of alternative anti-cancer therapy or time of last contact. Percentiles represent a set of points on a scale arrived at by dividing a group into parts in order of magnitude.

    Time frame: Week 0 to Week 19 when endpoints were met

  2. Overall Survival

    Kaplan-Meier Estimate. Overall survival is defined as time from start of treatment until death due to any cause. Subjects who are alive at the time of analysis will be censored at the time of last contact.

    Time frame: Week 0 to Week 98

  3. Response Duration

    The time from initial documented response to the first documented sign of progression or death due to progressive disease. Not calculated due to no Complete response and only 1 partial response.

    Time frame: Week 0 to week 98

  4. Time to Response

    The time from start of treatment until the first documented response. Not calculated due to no Complete response and only 1 partial response.

    Time frame: Week 0 to week 98

  5. Safety and Tolerability as Summarized Through Adverse Event Reporting

    AE = Adverse Event reported at a frequency of greater than or equal to 16%. SAE = Serious Adverse Events where all were reported at 0% frequency.

    Time frame: Week 0 to week 98

07

Results

Posted Jan 28, 2010
Limitations and caveats
As there was only 1 responder, time to response, and duration of response were not calculated.

Participant flow

Participant flow — Overall Study
MilestoneTopotecan Hydrochloride
Started37
Completed26
Not completed11
Withdrew: Sponsor terminated study9
Withdrew: Protocol violation1
Withdrew: Other (disease progression)1

Outcome measures

PrimaryBest Overall Response

Tumor response based on GOG (Gynecological Oncology Group) modified RECIST (Response Evaluation Criteria In Solid Tumors) criteria. A 4-point scale used specifying tumor response. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions; (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; (PD): At least a 20% increase in the sum of the LD of target lesions

Time frame:
Week 0 to Week 98 when endpoints were met
Reported as:
Number · Participants
Best Overall Response
ParticipantsTopotecan Hydrochloride
Complete Response0
Partial Response1
Stable Disease9
Progressive Disease23
Unknown4
SecondaryTime to Progression

Kaplan-Meier Estimate. Time to progression is defined as time from start of treatment until the first documented sign of disease progression or death due to progressive disease. Subjects who have not progressed or died at the time of analysis will be censored at the time of initiation of alternative anti-cancer therapy or time of last contact. Percentiles represent a set of points on a scale arrived at by dividing a group into parts in order of magnitude.

Time frame:
Week 0 to Week 19 when endpoints were met
Reported as:
Mean · Weeks
Time to Progression
WeeksTopotecan Hydrochloride
25th percentile7.3 (6.9 to 8.1)
Median percentile8.7 (7.9 to 11.1)
75th percentile15.3 (9.0 to 19.1)
SecondaryOverall Survival

Kaplan-Meier Estimate. Overall survival is defined as time from start of treatment until death due to any cause. Subjects who are alive at the time of analysis will be censored at the time of last contact.

Time frame:
Week 0 to Week 98
Reported as:
Mean · Weeks
Overall Survival
WeeksTopotecan Hydrochloride
25th percentile20.4 (10.1 to 31.7)
Median percentile47.3 (25.7 to 69.7)
75th percentile89.3 (61.6 to 98.1)
SecondaryResponse Duration

The time from initial documented response to the first documented sign of progression or death due to progressive disease. Not calculated due to no Complete response and only 1 partial response.

Time frame:
Week 0 to week 98
Reported as:
Mean · Weeks

No measurements were reported for this outcome.

SecondaryTime to Response

The time from start of treatment until the first documented response. Not calculated due to no Complete response and only 1 partial response.

Time frame:
Week 0 to week 98
Reported as:
Mean · Hours

No measurements were reported for this outcome.

SecondarySafety and Tolerability as Summarized Through Adverse Event Reporting

AE = Adverse Event reported at a frequency of greater than or equal to 16%. SAE = Serious Adverse Events where all were reported at 0% frequency.

Time frame:
Week 0 to week 98
Reported as:
Number · Number of Events
Safety and Tolerability as Summarized Through Adverse Event Reporting
Number of EventsTopotecan Hydrochloride
AE: Fatigue15
AE: Nausea14
AE: Constipation12
AE: Abdominal Pain11
AE: Vomiting8
AE: Hypokalemia7
AE: Anorexia6
AE: Dyspnea6
AE: Diarrhea6
AE: Dizziness6
AE: Headache6
AE: Insomnia6
SAE: Abdominal Pain2
SAE: Gastrointestinal hemorrhage1
SAE: Intestinal obstruction1
SAE: Rectal Hemorrhage1
SAE: Vomiting1
SAE: Pulmonary Embolism3
SAE: Dyspnea1
SAE: Bacteremia1
SAE: Streptococcal Bacteremia1
SAE: Cerebral ischemia1
SAE: Cerebral infarction1
SAE: Incisional hernia, obstructive1
SAE: Dehydration1
SAE: Embolism venous1
Alive at last contact-when follow-up ended9
Deaths - any subject28
Cause of Death - Disease of Study25
Cause of Death - Non-Hematological toxicity2
Cause of Death - Other-Brain Metastases1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Topotecan Hydrochloride———
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventTopotecan Hydrochloride
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders3/37
Abdominal painGastrointestinal disorders2/37
Gastrointestinal hemorrahageGastrointestinal disorders1/37
Intestinal ObstructionGastrointestinal disorders1/37
Rectal hemorrhageGastrointestinal disorders1/37
VomitingGastrointestinal disorders1/37
DyspneaRespiratory, thoracic and mediastinal disorders1/37
BacteremiaInfections and infestations1/37
Streptococcal InfectionInfections and infestations1/37
Incisional hernia obstructiveMusculoskeletal and connective tissue disorders1/37
Most frequent other events
Showing 10 of 43
Most frequent other events
EventTopotecan Hydrochloride
FatigueGeneral disorders15/37
NauseaGastrointestinal disorders14/37
ConstipationGastrointestinal disorders12/37
Abdominal painGastrointestinal disorders11/37
VomitingGastrointestinal disorders8/37
HypokalemiaMetabolism and nutrition disorders7/37
AnorexiaMetabolism and nutrition disorders6/37
DyspneaRespiratory, thoracic and mediastinal disorders6/37
DiarrheaGastrointestinal disorders6/37
DizzinessGeneral disorders6/37

Baseline characteristics

Age Continuous
Age Continuous(years)Topotecan Hydrochloride
Mean62.8 ± 9.12
Sex: Female, Male
Sex: Female, Male(Participants)Topotecan Hydrochloride
Female37
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Topotecan Hydrochloride
Caucasian34
African Heritage/African American3
08

Study locations

24 sites
  • GSK Investigational Site
    LaJolla, California 92037, United States
  • GSK Investigational Site
    Los Angeles, California 90033, United States
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    Engelwood, Colorado 80113, United States
  • GSK Investigational Site
    Coral Gables, Florida 33146, United States
  • GSK Investigational Site
    Lakeland, Florida 33805, United States
  • GSK Investigational Site
    Miami, Florida 33143, United States
  • GSK Investigational Site
    Orlando, Florida 32804, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    Hinsdale, Illinois 60521, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70115, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55455, United States
  • GSK Investigational Site
    Lincoln, Nebraska 68510, United States
  • GSK Investigational Site
    Columbia, South Carolina 29210, United States
  • GSK Investigational Site
    Greenville, South Carolina 29605, United States
  • GSK Investigational Site
    Chattanooga, Tennessee 37403, United States
  • GSK Investigational Site
    Knoxville, Tennessee 37917, United States
  • GSK Investigational Site
    Seattle, Washington 98104, United States
  • GSK Investigational Site
    Calgary, Alberta T2N 4N2, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4M1, Canada
  • GSK Investigational Site
    Quebec, G1R 2J6, Canada
  • GSK Investigational Site
    Debrecen, 4032, Hungary
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2005
First posted
Dec 21, 2005
Start
Oct 2005
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Results first posted
Jan 28, 2010
Last update
Jul 11, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00267488
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 21, 2005
Start date
Oct 2005
Primary completion
Dec 2007
Completion
Dec 2007
Results posted
Jan 28, 2010
Last update
Jul 11, 2012

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Topotecan

Start the discussion